Zacks Rating on Illumina (ILMN)

Illumina (ILMN) : The consensus on Illumina (ILMN) based on 15 analyst recommendation on the company stock is 2.55, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Illumina (ILMN) : 10 Wall Street analysts covering Illumina (ILMN) believe that the average level the stock could reach for the short term is $152.1. The maximum price target given is $180 and the minimum target for short term is around $115, hence the standard deviation is calculated at $20.63.


Shares of Illumina Inc. rose by 1.85% in the last five trading days and 14.7% for the last 4 weeks. Illumina Inc. is up 20.43% in the last 3-month period. Year-to-Date the stock performance stands at -9.98%. Illumina (NASDAQ:ILMN): On Tuesdays trading session , Opening price of the stock was $173.9 with an intraday high of $174.84. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $171.6. However, the stock managed to close at $172.79, a loss of 0.55% for the day. On the previous day, the stock had closed at $173.75. The total traded volume of the day was 674,208 shares.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.